4 hrs ago | Freshnews
Surveyed U.S. Rheumatologists and MCO Pharmacy Directors Agree That a ...
Surveyed U.S. Rheumatologists and MCO Pharmacy Directors Agree That a Drug's Effect on the Signs and Symptoms of Rheumatoid Arthritis is One of the Attributes That Most Influences Their Decisions Rega BURLINGTON, Mass.
Patienta s Access to Treatments Act: Get the Meds You Need
When you have rheumatoid arthritis, medication can be an essential part of controlling the disease and managing symptoms.
Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences
A webcast of this presentation will be available at www.protalix.com on the event calendar page and a replay will be archived and available after the conference for 30 days.
Arthritis Therapeutics Market to 2018 Report Available From MarketResearchReports.in
The new report* examines how arthritis therapeutics are becoming a gigantic attraction in the global pharmaceutical industry as the condition is increasingly considered to be one of the most common causes of disabilities.
Therapeutic effect of the combination of etanercept and methotrexate...
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial by: Lars Klareskog , Desiree van der Heijde , Julien P. de Jager , Andrew Gough , Joachim Kalden , Michel Malaise , Emilio M. Mola , Karel Pavelka , Jacques Sany , ... (more)
BUYINS.NET: Market Maker Surveillance Report. PFE, SIRI, MU, CSCO,...
BUYINS.NET: Market Maker Surveillance Report. PFE, SIRI, MU, CSCO, CLWR, QQQ, Highest Net Sell Volume and Negative Price Friction For Tuesday, May 15th 2012 BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday.
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
343, No. 22. , pp. 1586-1593, doi:10.1056/nejm200011303432201 Etanercept is a soluble tumor necrosis factor receptor fusion protein that binds and inactivates TNF, a proinflammatory cytokine that is overproduced in the joints of patients with rheumatoid arthritis.1 Etanercept reduces disease activity in adults and children with chronic rheumatoid ... (more)
Advisory Panel Recommends FDA Approval Of...
An advisory panel recommends that the U.S. Food and Drug Administration consider approving Pfizer's pill to treat rheumatoid arthritis.
New rheumatoid arthritis pill tofacitinib backed by FDA panel
A new rheumatoid arthritis drug considered to be the first of its kind got backed by a Food and Drug Administration advisory panel Wednesday, putting the drug a step closer to hitting the market.
FDA Recommendations Bode Well For Pfizer
Pfizer is still transitioning itself after its best selling drug Lipitor went off patent in 2011.
Customer Interaction Solutions
BUYINS.NET: Market Maker Surveillance Report. PFE, BAC, GE, WFC,...
BUYINS.NET: Market Maker Surveillance Report. PFE, BAC, GE, WFC, INTC, YHOO, Highest Net Sell Volume and Negative Price Friction For Wednesday, May 9th 2012 BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday.
Forget the vampire and ghost shows - the scariest things on national TV are the prescription medicine advertisements.
Pfizer Rheumatoid Arthritis Pill Looks 'Approvable'
Will theA Pfizer pill for rheumatoid arthritis - the first oral biologic for treating this ailment -A pass muster with the FDA? Wall Street continues to bet its drug will win approval, butA agency briefing documents released in advance of an advisory panel meeting this weekA raiseA raise some tough questionsA about what the drugmaker hopes will ... (more)
Awareness and Action with The Arthritis Foundation
Meet Amelia and Liberty Shultz. They are four and two and half years old and are this year's National Arthritis Walk youth honorees , selected to represent the 300,000 kids in the US who live with juvenile arthritis Amelia was diagnosed at 23 months and Liberty at 13 months.
Protalix BioTherapeutics to Review FDA Approval of ELELYSO
Protalix BioTherapeutics, Inc. , announced today the Company has scheduled a conference call and webcast for Wednesday, May 2, 2012 at 8:00 AM EDT to review the U.S. Food and Drug Administration's approval of ELELYSO for the treatment of Type 1 Gaucher disease.
Also on Topix